BPC-157 dosing — commonly cited daily range

The figure most often cited in research-peptide communities is roughly 250–500 mcg per day, taken as a single subcutaneous injection or split into two, usually in cycles of several weeks. That number is a community convention, not a validated dose: no human dose-finding study of BPC-157 has ever been published, and human pharmacokinetics — how fast it is absorbed and cleared — remain uncharacterized in the peer-reviewed literature (Józwiak et al., Pharmaceuticals 2025).

Framed as what is reported, not what is advised:

• Community and anecdotal logs: roughly 250–500 mcg once or twice daily by subcutaneous injection, in multi-week cycles; sometimes injected near the area of interest, though localized advantage is unproven in humans.

• Animal studies: weight-based dosing, most commonly 10 mcg/kg — for example 10 mcg/kg/day intraperitoneally for four weeks in a 2026 rat Achilles-tendon study (Biçer et al., Jt Dis Relat Surg 2026). Rodent ligament work also used oral dosing in drinking water and topical application (Cerovecki et al., J Orthop Res 2010).

• The one published human report: a retrospective knee-pain case series used intra-articular injections administered by physicians in a clinic — a route and setting that has nothing in common with self-administered subcutaneous use (Lee & Padgett, Altern Ther Health Med 2021).

The 250–500 mcg convention appears to be a loose extrapolation of the rodent 10 mcg/kg range to a human body weight (10 mcg/kg × 70 kg = 700 mcg, commonly rounded down). That arithmetic skips every step a real dose-translation would require: interspecies allometric scaling, route differences (intraperitoneal in rats vs subcutaneous in people), absorption and half-life data, and dose-response work in humans — none of which exist for BPC-157. It also inherits the variability of the animal literature itself, where effective doses differ across models and where a recent independent study found BPC-157's tendon effects mostly short of statistical significance at that standard dose (Biçer et al. 2026). In short: the community number is downstream of rat protocols, not of any human evidence.

BPC-157 is supplied as lyophilized (freeze-dried) powder that is dissolved in bacteriostatic water before use. Two mechanical points account for most reported dosing errors:

• Concentration is set by reconstitution: 5 mg of powder in 2 mL of water yields 2.5 mg/mL; the same vial in 5 mL yields 1 mg/mL. The syringe volume that corresponds to any microgram amount depends entirely on this choice.

• Insulin-syringe "units" are volume, not dose: reading units as micrograms is a common and significant error.

The peptide calculator maps vial size, diluent volume, and per-dose volume — it converts numbers; it does not make any number appropriate. Oral capsule products also exist; rodent data showing oral activity (Cerovecki et al. 2010) make oral dosing less implausible than for most peptides, but no human study has compared oral and injectable routes.

Because BPC-157 is unapproved, there are no established contraindications, no drug-interaction data, and no human safety dataset — the FDA states it has "no, or only limited, safety-related information" on the compound (FDA bulk drug substances list). Athletes should also know that any use, at any dose, is a potential anti-doping violation: BPC-157 is prohibited at all times under WADA category S0, and sanctions have been imposed without a positive test. The community figures above describe what people report doing; a clinician remains the only appropriate source for individual decisions.

For broader context, see the main BPC-157 reference page and the side-effects and safety page.